The annual meeting of the American Society für Clinical Oncology (ASCO) took place again in Chicago. New results of clinical studies with advanced stage melanoma was presented. Dr. Okamoto reports from the post ASCO meeting where key results were highlighted.
See also: Dr. Okamoto on Facebook
Dr. Okamoto informs about improved survival of advanced stage melanoma
Until a few years ago, DTIC (chemotherapy) has been used as standard therapy in advanced stage melanoma with a poor efficacy for more than 35 years. The overall survival of the treated patients was 10 months. Now, with novel regimen which show even improved efficacy in combination, survival of patients could be significantly improved to 25 months. The ipilimumab and nivolumab combination (both antibodies against a cell surface antigen) might prove to be even more promising.
Please contact our office per phone under +43 1 40114, EXT 5701, 5702 or 5703, by email to email@example.com, or by filling out the electronic contact form!